Optimal SMBG (self-monitoring of blood glucose) practice is associated with improvement in glycemic control in different types of patients


Impact of SMBG on A1C levels in patients with diabetes1

Goals for glycemic management include A1C reduction, FPG lowering, and PPG control

Glycemic targets

 

Target ADA2 AACE3 IDF4
A1C (%) <7% <6.5% <6.5%
FPG (mg/dL) 70-130 <110 <100
2-hour PPG (mg/dL) <180 <140 <140

According to the ADA guidelines, a patient’s glycemic goals should individualized, with personal targets based on the following factors2:

  • Duration of diabetes
  • Age/life expectancy
  • Comorbid conditions
  • Known CVD or advanced microvascular complications
  • Hypoglycemia unawareness
  • Individual patient considerations

Postprandial hyperglycemia is an important target for glycemic control4

  • Patients with type 2 diabetes may spend more than 16 hours in the state of postprandial hyperglycemia6
  • Elevated PPG is an independent risk factor for macrovascular disease4
  • SMBG may be a useful method for assessing plasma glucose, promotes timely treatment adjustment and intensification, and provides the most practical method for measuring PPG2,4

PPG is an important glycemic target and contributes significantly to overall glycemia in patients with an A1C level below 9.3%.1-5,7

  • Each 1%-point reduction in A1C levels is associated with a lower risk of microvascular and macrovascular complications, as well as lower healthcare costs8,9

Bayer’s unique portfolio offers testing features to help optimize your patients’ SMBG practice. Training videos are available to help you educate your patients on the benefits and proper use of these features.

Bayer Products

References

  1. Karter AJ et al. Am J Med. 2001;111:1-9.
  2. ADA. Diabetes Care. 2010;33(suppl)1:S11-S61.
  3. AACE. Endocr Pract. 2007;13(suppl)3:3-68.
  4. IDF. Guideline for management of postmeal glucose. 2007. http://www.idf.org/webdata/docs/guideline_PMG_final.pdf
  5. Monnier L et al. Diabetes Care. 2003;26:881-885.
  6. Hanefeld M and Schaper F. Curr Diab Rep. 2005;5:333-339.
  7. Monnier L and Colette C. Curr Diab Rep. 2008;8:368-374.
  8. Gilmer TP et al. Diabetes Care. 2005;28:59-64.
  9. Stratton IM et al. BMJ. 2000;321:405-412.